Kailin Xu
The Affiliated Hospital oh Xuzhou Medical University · Xuzhou Medical University · The Affiliated Hospital of Xuzhou Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kailin Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07070934 · CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?Xuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- N/ANCT07070960 · A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligibleXuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- Ph2NCT06963866 · Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCTXuzhou Medical University · not yet recruiting · Multiple Myeloma, Newly Diagnosed · study chair
- Ph1/Ph2NCT06196255 · Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)Xuzhou Medical University · recruiting · Multiple Myeloma · study chair
- Ph1/Ph2NCT06132711 · Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple MyelomaXuzhou Medical University · recruiting · Multiple Myeloma · study chair
- Ph1/Ph2NCT06125652 · Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)Xuzhou Medical University · recruiting · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse · study chair
- Early Ph1NCT05744440 · Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCTXuzhou Medical University · unknown · Acute Myeloid Leukemia · principal investigator
- Early Ph1NCT05739227 · Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesXuzhou Medical University · unknown · Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT05509530 · Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)Xuzhou Medical University · unknown · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT05488132 · Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)Xuzhou Medical University · unknown · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse · principal investigator
- Ph1NCT04814004 · Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell TumorsKai Lin Xu; Jun Nian Zheng · unknown · Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia · study chair
- Ph1/Ph2NCT02794961 · CD22 Targeting CAR-T Therapy Against B Cell Hematological MalignanciesKai Lin Xu; Jun Nian Zheng · unknown · Recurrent or Refractory B Cell Malignancy · principal investigator
- Ph1/Ph2NCT02782351 · Humanized CAR-T Therapy for Treatment of B Cell MalignancyKai Lin Xu; Jun Nian Zheng · unknown · Leukemia, Lymphocytic, Chronic, B-Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:13 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.Lancet Haematol · 2019286 citationsRCR 9.6
- Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.J Clin Oncol · 2022121 citationsRCR 7.3
- Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.Nat Commun · 2024107 citationsRCR 11.7
- 93 citationsRCR 7.4
- Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.Lancet Haematol · 202463 citationsRCR 6.9
- Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.Front Immunol · 202229 citationsRCR 1.7
- Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.Lancet Haematol · 202525 citationsRCR 4.9
- Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma.Hematology · 201619 citationsRCR 0.6
- Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.Transplant Cell Ther · 202112 citationsRCR 0.5